{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:23:08Z","timestamp":1793064188891,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]},{"name":"This study was funded by Janssen Research & Development, LLC and Legend Biotech, Inc.","id":[{"id":"https:\/\/ror.org\/05wae1a98","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed\/refractory MM (RRMM). Patients (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009248; ECOG performance status of 0\u20131, \u22653 prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1\u201320) cycles of SOC therapy. Overall response rate was 29.8% (95%\u2009CI: 24.2\u201336.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95%\u2009CI: 3.9\u20135.6) and 12.4 months (95%\u2009CI: 10.3\u2013NE). Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3\/4). Altogether, 107 deaths occurred, due to progressive disease (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200974), TEAEs (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200919), and other reasons (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200914). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action.\n                  <\/jats:p>","DOI":"10.1038\/s41375-022-01531-2","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T21:03:39Z","timestamp":1648155819000},"page":"1371-1376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":245,"title":["LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria-Victoria","family":"Mateos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-6614","authenticated-orcid":false,"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-5827","authenticated-orcid":false,"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-0035","authenticated-orcid":false,"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4514-3227","authenticated-orcid":false,"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Lindsey-Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Dytfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Angelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique M.","family":"Ocio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8619-412X","authenticated-orcid":false,"given":"Francesca","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Roeloffzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodriguez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek","family":"Broijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Potamianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caline","family":"Sakabedoyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Semerjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Keim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Strulev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Schecter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wapenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonia","family":"Nesheiwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jesus","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0808-2237","authenticated-orcid":false,"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-0819","authenticated-orcid":false,"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"1531_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0065-8","volume":"8","author":"P Ravi","year":"2018","unstructured":"Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8:26.","journal-title":"Blood Cancer J"},{"key":"1531_CR2","doi-asserted-by":"publisher","first-page":"204062071882266","DOI":"10.1177\/2040620718822660","volume":"10","author":"LE Franssen","year":"2019","unstructured":"Franssen LE, Mutis T, Lokhorst HM, van de Donk N. Immunotherapy in myeloma: how far have we come? Ther Adv Hematol. 2019;10:2040620718822660.","journal-title":"Ther Adv Hematol"},{"key":"1531_CR3","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u201375.","journal-title":"Leukemia"},{"key":"1531_CR4","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/leu.2015.290","volume":"29","author":"BG Durie","year":"2015","unstructured":"Durie BG, Miguel JF, Blade J, Rajkumar SV. Clarification of the definition of complete response in multiple myeloma. Leukemia. 2015;29:2416\u20137.","journal-title":"Leukemia"},{"key":"1531_CR5","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"Lancet Oncol"},{"key":"1531_CR6","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R. et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691\u20135.","journal-title":"Blood"},{"key":"1531_CR7","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","volume":"31","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H. et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443\u201348.","journal-title":"Leukemia"},{"key":"1531_CR8","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","volume":"21","author":"S Usmani","year":"2016","unstructured":"Usmani S, Ahmadi T, Ng Y, Lam A, Desai A, Potluri R, et al. Analysis of real-world data on overall survival in multiple myeloma patients with >\/=3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;21:1355\u201361.","journal-title":"Oncologist"},{"key":"1531_CR9","doi-asserted-by":"publisher","first-page":"8030","DOI":"10.1200\/JCO.2021.39.15_suppl.8030","volume":"39","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, Lin Y, Martin TG, Chhabra S, Usmani SZ, Jagannath S, et al. Cilta-cel versus conventional treatment in patients with relapse\/refractory multiple myeloma. J Clin Oncol. 2021;39:8030\u201330.","journal-title":"J Clin Oncol"},{"key":"1531_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1182\/blood-2020-137164","volume":"136","author":"J Blade Creixenti","year":"2020","unstructured":"Blade Creixenti J, Mateos M-V, Oriol A, Larocca A, Cavo M, Rodr\u00edguez-Otero P. et al. HORIZON (OP-106) Versus MAMMOTH: an indirect comparison of efficacy outcomes for patients with relapsed\/refractory multiple myeloma refractory (RRMM) to anti-CD38 monoclonal antibody therapy treated with melflufen plus eexamethasone versus conventional agents. Blood. 2020;136:2\u20134.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01531-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01531-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01531-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T07:09:29Z","timestamp":1651475369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01531-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1531"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01531-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"assertion":[{"value":"30 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M-VM: honoraria\/member on the board of directors\/advisory committees (Amgen, Adaptive Biotechnologies, BMS Celgene, Janssen, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, Sea-Gen, Takeda). KW: honoraria (Roche); consultant\/honoraria (Adaptive Biotech, Karyopharm, Takeda); honoraria\/membership on board of directors\/advisory committees (BMS, Celgene, Amgen, GSK, Janssen, Oncopeptides, Sanofi). VDS: honoraria (Abbvie, Alexion, Amgen, AOP Pharmaceutical, BMS Celgene, Grifols, GSK, Sanofi, SOBI, Takeda); honoraria\/research funding (Novartis). HG: honoraria (GSK); consultant (Adaptive Biotech); research funding (Incyte, Johns Hopkins University, Molecular Partners, MSD, Mundipharma); honoraria\/research funding (Novartis); honoraria\/research funding (Chugai); consultant\/ honoraria\/research funding (Amgen, BMS, Celgene, Janssen, Sanofi). MD: honoraria\/research funding (Amgen, Celgene, Janssen, Sanofi). MM: honoraria (Amgen, Astellas, BMS, Gilead, Takeda, Novartis, Pfizer, Adaptive Biotech); honoraria\/research funding (Celgene, Sanofi). MC: honoraria (Novartis); honoraria\/consultant (GSK, Adaptive Biotech); honoraria\/consultant, membership on board of directors\/advisory committees\/speakers bureau (BMS, Sanofi, AbbVie, Amgen, Takeda); honoraria\/consultant\/member of board of directors\/advisory and speakers bureaus\/travel accommodations and expenses (Janssen, Celgene). DD: employee\/consultant\/ honoraria\/member of board of directors\/advisory committees (Janssen Cilag); member of board of directors\/advisory committees\/research funding (Celgene). AuP: honoraria (AbbVie, Amgen, BMS Celgene, GSK); honoraria\/research funding (Sanofi); honoraria\/member of board of directors\/advisory committees (Janssen); honoraria\/research funding\/member of board of directors\/advisory committees (Takeda). RB: honoraria\/research funding (Allogene, Janssen, BMS, Gilead, Servier). NWCJvdD: research funding (Cellectis), consultant (Takeda, Roche, Novartis, Bayer, Servier); research funding\/consultant (Janssen, Amgen); consultant\/honoraria (BMS Celgene). EMO: consultant (Sanofi, Oncopeptides); consultant\/honoraria (Janssen, Takeda); consultant\/honoraria\/research funding (Amgen, BMS Celgene). ChS: honoraria (AbbVie); consultant (Roche); honoraria\/member of board of directors\/advisory committees (Novartis, Takeda); consultant\/honoraria\/member of board of directors\/advisory committees (Amgen, BMS, Janssen). FG: honoraria (BMS); consultant\/honoraria (Sanofi); member of board of directors\/advisory committees (Roche, Adaptive Biotech, Oncopeptides, Bluebird Bio); honoraria\/member of board of directors\/advisory committees (Amgen, Celgene, Janssen, Takeda, AbbVie, GSK). PR-O: honoraria\/speaker bureaus (BMS Celgene, Janssen, Amgen, GSK, Sanofi, Regeneron, Oncopeptides). AB: honoraria (Amgen, BMS Celgene, Janssen, Sanofi). AnP, JMS: employees and holders of stock options at Janssen. CaS, MS, RW: employees of Janssen. SK: employee of Janssen R&D. VS: employee of Janssen Pharmaceutica NV. MV: employee of Janssen Global Services, LLC. TN: employee of Legend Biotech USA. JS-M: consultant\/member of board of directors\/advisory committees (AbbVie, Amgen, BMS Celgene, GSK, Janssen, Karyopharm, Merck Sharpe & Dohme, Novartis, Regeneron, Roche, Sanofi, Secura Bio, Takeda). PS: honoraria\/research funding (SkylineDx); consultant\/honoraria\/research (Amgen, BMS Celgene, Janssen, Karyopharm, Takeda). PM: honoraria (AbbVie, Amgen, Janssen, Sanofi, Celgene\/BMS, Oncopeptides). RV, JL-H, EA, WR, and HE: no relationships to disclose. Funded by Janssen Research & Development, LLC and Legend Biotech, Inc.; ClinicalTrials.gov identifier, NCT04035226.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}